As Provenge Sales Dip, Dendreon Hopes Restructuring Is The Answer
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite weaker sales of the cancer immunotherapy compared to the first quarter, the Seattle-based biotech insists it can stimulate demand.